Accenture plc vs Humana Inc — how do they compare? Accenture plc trades at $177.38 (market cap $110.04B), while Humana Inc trades at $384.38 (market cap $44.77B). The key difference: Accenture plc is far larger — about 2.5× Humana Inc's market cap, and Accenture plc pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| ACN | HUM | |
|---|---|---|
Market Cap | $110.04B | $44.77B |
Sector | Technology | Health |
52-Week High | $288.54 | $409.42 |
52-Week Low | $124.41 | $163.67 |
Enterprise Value | $108.26B | $52.12B |
Dividend Yield | 3.63% | 0.95% |
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $178.25, up 1.44% with strong technical and fundamental momentum. The stock shows bullish technical signals with support at $174 and resistance at $181, while recent earnings consistently beat expectations with Q1 2026 EPS of $3.80 versus $3.70 expected. Revenue growth accelerated to $69.67 billion in 2025, with solid profitability margins and attractive valuation metrics including P/E of 14.36. Recent partnerships with TEPCO and AlphaSense highlight ongoing AI-driven business transformation initiatives.
Outlook remains positive with analyst consensus price target of $189.77 offering 6.5% upside potential. Key opportunities include continued AI adoption and margin expansion, while risks involve competitive pressures and potential economic slowdown affecting consulting demand. The strong buy rating consensus (66% of analysts) supports continued investor confidence in the company's growth trajectory.
Humana (HUM) trades at $385.47, up 0.12% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue growth remains robust, reaching $129.66B in 2025, though net income margins have compressed to 0.88%. Recent news highlights leadership changes and Medicaid contract wins, while analyst consensus leans Hold with a $409.93 price target.
Outlook is mixed: Medicare Advantage margin expansion plans and cost controls offer upside, but regulatory pressures and margin erosion pose risks. The stock presents a cautious opportunity for investors betting on operational turnaround, with technical support near $382.
Trailing returns across standard periods
Latest headlines on both assets
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →